Gerhard Named OCG Director
Dr. Daniela S. Gerhard has been named director of NCI's Office of Cancer Genomics (OCG). She joined NCI in 2002 and has served as acting director of OCG since mid-2003.
Dr. Gerhard has spearheaded a number of OCG initiatives, including the Cancer Genome Anatomy Project, the human transcriptome program, and a pilot program to evaluate the technologies and process for an expanded human cancer genome project.
Dr. Gerhard received her undergraduate degree from Barnard College, earned her doctorate in genetics and molecular biology from Cornell University Graduate School of Medical Sciences, and performed postdoctoral work in human and cancer genetics at Massachusetts Institute of Technology. Prior to joining NCI, she was on the faculty of Washington University School of Medicine in St. Louis in the department of genetics.
Third Annual Cancer Survivorship Telephone Workshop Series
The program is a collaborative effort between NCI, CancerCare, the Lance Armstrong Foundation, the Intercultural Cancer Council, Living Beyond Breast Cancer, and the National Coalition for Cancer Survivorship.
The workshops are free; no telephone charges apply. To register, visit the CancerCare Web site at: http://www.cancercare.org/Feedback/Feedback.cfm?r=21&ii=1&ip=0%20. All workshops will take place via telephone Tuesdays from 1:00 p.m. to 2:00 p.m. ET on the following dates:
Part I: Care & Wellbeing After Treatment, April 12, 2005
Part II: Managing Long-term Lingering Side Effects, May 24, 2005
Part III: Health Promoting Behaviors: Things You Can Do, June 14, 2005
NCAB Quarterly Meeting Held
NCAB also heard from Dr. Anna Barker, NCI deputy director for strategic scientific initiatives, and Dr. Arthur Caplan, chair of the department of medical ethics at the University of Pennsylvania, on ethical issues and concerns surrounding biospecimens and biorepositories for post-genomics research. Dr. Caplan detailed several important areas that must be considered in sample collection, access, privacy, and confidentiality to secure public trust and ensure the future sharing of resources across the cancer research community. Although several issues were discussed, the development of consensus on approaches to consent, data anonymization, and access were considered key to future planning for biospecimens and biorepositories.